Sep 30, 2019

Neurocrine Biosciences Q3 2019 Earnings Report

Total Revenue
$222M
Previous year: $152M
+46.3%
EPS
$0.56
Previous year: $0.52
+7.7%
R&D Expense
$45.3M
SG&A Expense
$84.5M
Gross Profit
$220M
Previous year: $150M
+46.4%
Cash and Equivalents
$167M
Previous year: $196M
-14.9%
Free Cash Flow
$94.3M
Previous year: $56.6M
+66.7%
Total Assets
$1.18B
Previous year: $934M
+26.4%

Neurocrine Biosciences

Neurocrine Biosciences

Neurocrine Biosciences Revenue by Segment